24AUG

CEPI puts a Bundibugyo vaccine in trials

3 min read

17:07UTC

CEPI announced on 31 July that a vaccine candidate matched to Bundibugyo ebolavirus has entered production for clinical trials, with up to $8.5m behind it.

← Back to Guatemala's measles outbreak outgrew Mexico Jump to analysis ↓

ScienceDeveloping

Key takeaway

The first vaccine matched to this Ebola species reaches production too late to affect this outbreak.

The Coalition for Epidemic Preparedness Innovations (CEPI) announced on Friday 31 July that a vaccine candidate specific to Bundibugyo ebolavirus has entered production for clinical trials ¹. Hilleman Laboratories of Singapore, a joint venture between Merck & Co. (known as MSD outside the United States and Canada) and the Wellcome Trust, is developing it on the rVSV platform, a live vesicular stomatitis virus engineered to carry an Ebola surface protein, using a reference virus supplied by the International AIDS Vaccine Initiative (IAVI). CEPI is committing up to $8.5m, alongside a separate $30m programme improving MSD's manufacturing of the licensed Zaire-strain vaccine.

The licensed rVSV-ZEBOV vaccine, the one that ring-vaccinated its way through West Africa and eastern DR Congo, protects against Zaire ebolavirus only, and so do the two licensed antibody treatments, Inmazeb and Ebanga. Bundibugyo's surface glycoprotein, the target all three products are built around, differs enough from Zaire's that none of them cross-protects, so the candidate had to be made rather than borrowed. Uganda's 28 July declaration release states in terms that no licensed vaccine or targeted treatment exists for Bundibugyo ², a primary-source statement of the gap rather than an inference. CEPI has been buying toward it since June, when it awarded $1.9m for a fourth Bundibugyo rVSV seed stock .

Eleven weeks into the third-largest Ebola outbreak on record, the first species-matched candidate is entering trial production. Vaccine development rarely moves faster, and the honest reading of the announcement is that it protects nobody in Ituri this year: a candidate that begins production in July has no efficacy data, no regulatory dossier and no doses in the field while transmission continues. Its value is to the outbreak after this one, which for a species with three recorded outbreaks in nineteen years is a serious argument rather than a consolation.

This is a separate programme from the randomised treatment trial that began dosing patients in Ituri on 2 July , which tests remdesivir, MBP134 and obeldesivir in people already infected. A vaccine trains an uninfected immune system; those three are given to patients WHO already have the virus.

Deep Analysis

In plain English

There is currently no approved vaccine or treatment that works against the specific type of Ebola causing this outbreak, called Bundibugyo ebolavirus. The vaccines and drugs that do exist and are already approved, including the well-known Ervebo vaccine, were built against a different type, Zaire ebolavirus, the one behind the 2014-16 West Africa epidemic and the 2018-20 Kivu epidemic. The two types are different enough that protection against one does not carry over to the other. CEPI, a global vaccine-funding organisation, has now put up to $8.5m behind a new vaccine candidate built specifically for Bundibugyo, developed by a Singapore-based lab called Hilleman Laboratories. It has just entered production for clinical trials, the first step toward eventually testing it in people.

Deep Analysis

Root Causes

Bundibugyo ebolavirus's glycoprotein, the surface protein a vaccine or antibody treatment must target, differs enough from Zaire ebolavirus's that antibodies raised against one do not neutralise the other; this is a molecular fact, not a regulatory choice, and it is why Inmazeb, Ebanga and the Ervebo vaccine, all developed and licensed against Zaire ebolavirus, offer no protection here despite being proven products.

Building a new candidate against a different glycoprotein takes real time even on an established rVSV platform: sourcing a reference virus, here supplied by IAVI, re-engineering the vector, and clearing safety review before clinical-trial production can begin are sequential steps that cannot be skipped, which is why the first species-matched candidate is only now entering trial production eleven weeks into the outbreak.

What could happen next?

Meaning
No licensed vaccine or targeted treatment currently protects against Bundibugyo ebolavirus, the species behind this outbreak, because existing licensed products target the molecularly distinct Zaire ebolavirus.
Consequence
Even with production now underway, a species-matched vaccine will not be available to patients in the current outbreak, since clinical trials and regulatory review take substantially longer than the outbreak's likely duration.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The licensed Zaire-strain vaccine rVSV-ZEBOV took roughly two decades from initial development to full licensure, spanning the 2014-16 West Africa epidemic before regulatory approval arrived; a Bundibugyo-specific candidate reaching trial production within the outbreak's first eleven weeks is dramatically faster, reflecting platform reuse rather than starting from nothing.

Counter-parallel: The 2012 Isiro Bundibugyo outbreak, at 38 cases, ended before any species-specific vaccine development was pursued at all, since a 38-case outbreak did not generate the funding or trial-population scale needed to justify it; the current outbreak's scale, the third-largest Ebola outbreak on record, is what has made a dedicated candidate viable this time.

Consensus view: CEPI frames the Hilleman Laboratories candidate, developed with an IAVI reference virus and MSD manufacturing, as closing a specific gap: the licensed rVSV-ZEBOV vaccine and antibody treatments Inmazeb and Ebanga all target Zaire ebolavirus and, per Uganda's own 28 July release, do not cross-protect against Bundibugyo, so no licensed countermeasure exists for the species actually circulating in this outbreak.

Counter-view: Vaccine manufacturing specialists note CEPI's parallel $30m programme improving MSD's Zaire-strain manufacturing reflects a deliberate hedge: building out capacity for the vaccine that already works, even against the wrong species for this outbreak, because a species-matched candidate's trial timeline cannot be compressed regardless of funding.

Key tension: Whether the priority should be accelerating the Bundibugyo-specific candidate as fast as possible, or maintaining and expanding Zaire-strain capacity in case a future outbreak is caused by that species instead, since the two development tracks compete for some of the same manufacturing and regulatory attention.

Sources:Actualite.cd

Mentions:CEPI →IAVI →Bundibugyo ebolavirus →Inmazeb →MBP134 →Canada →Ebanga →Singapore →Ervebo →Zaire ebolavirus →United States →DR Congo →Uganda →Ituri Province →Hilleman Laboratories →Merck & Co. →Wellcome Trust →

First Reported In

Update #12 · Two-thirds of Ebola deaths never reach a ward

Actualite.cd· 31 Jul 2026

Read original →

Causes and effects

Caused by

CEPI funds a fourth Ebola vaccine

CEPI's June seed-stock award for a fourth Bundibugyo candidate precedes this candidate entering trial production.

Occurred 8 Jun 2026

Read story →

This Event

CEPI puts a Bundibugyo vaccine in trials

The licensed Ebola vaccine covers a different species, so the outbreak now in its eleventh week has been fought without a matched vaccine or targeted treatment.

Led to

Moderna doses first human in Truro

CEPI's 31 July move to put the first Bundibugyo-specific candidate into trial production preceded Moderna's first human dose.

Occurred 2 Aug 2026

Read story →

Different Perspectives

UK Health Security Agency

UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.

GLEWS+

GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.

WHO Regional Office for Africa

WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.

People in Guatemala

Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.

Pan American Health Organization

PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.